Mkt Cap$2.27T-0.02%
24h Vol$65.67B
BTC Dom56.4%
ETH Dom9.8%
F&G25Extreme Fear
BTC$63,870.00+0.23% ETH$1,839.31-1.23% USDT$0.9993+0.01% BNB$567.66-0.67% USDC$0.9999+0.00% XRP$1.09+0.24% SOL$74.99-0.32% TRX$0.3225-0.10% FIGR_HELOC$1.03+2.52% HYPE$59.73-2.05% DOGE$0.0725+0.31% USDS$0.99980.00% RAIN$0.0141-2.89% ZEC$545.16+3.51% LEO$9.80-0.01% WBT$55.71-0.05% BTC$63,870.00+0.23% ETH$1,839.31-1.23% USDT$0.9993+0.01% BNB$567.66-0.67% USDC$0.9999+0.00% XRP$1.09+0.24% SOL$74.99-0.32% TRX$0.3225-0.10% FIGR_HELOC$1.03+2.52% HYPE$59.73-2.05% DOGE$0.0725+0.31% USDS$0.99980.00% RAIN$0.0141-2.89% ZEC$545.16+3.51% LEO$9.80-0.01% WBT$55.71-0.05%
News

RZLT

Total Stories
1
Section
RZLT
Rezolute Shares Collapse 90% After Late-Stage Study Misses Primary Endpoint
Market Analysis

Rezolute Shares Collapse 90% After Late-Stage Study Misses Primary Endpoint

Rezolute shares plunged 90% in premarket trading after its Phase 3 trial for ersodetug failed to show meaningful benefit in treating congenital hyperinsulinism.

Tim FriesDec 11, 20253 min read